Personalized ATG dosing may reduce transplant complications
NCT ID NCT05166967
First seen Jan 25, 2026 · Last updated May 13, 2026 · Updated 21 times
Summary
This study looked at 204 patients receiving a stem cell transplant from a half-matched donor. Researchers compared two different doses of a drug called ATG to see which one better prevents graft-versus-host disease (a condition where donor cells attack the patient's body) and reduces virus reactivation. The goal is to improve outcomes for patients needing this type of transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.